Dexcom‘s (Nasdaq:DXCM) C-suite is seeing another of its members take on multiple roles. Its chief financial officer will now also serve as chief operating officer. Jereme Sylvain joined the diabetes tech company in 2018, and has been its CFO and executive VP since 2021. His new COO hat will add oversight of Dexcom’s global operations […]
MassDevice Diabetes Hub
MassDevice's Diabetes Hub is your resource for the latest news in diabetes technology. Stay informed about the innovations and business news shaping the diabetes device industry.
Check out our latest feature:
Here are more top diabetes features from MassDevice, Drug Delivery Business News and sibling publications (and scroll down to read the latest diabetes device news from MassDevice):
+ The 10 largest diabetes tech companies in the world in 2026
+ 6 diabetes tech companies you need to know
+ Diabetes Technology Innovations Special Report — 2026
+ MiniMed flexes with next-gen insulin pump
+ The biggest diabetes tech news out of ADA 2026
+ 12 things you need to know about the CGM market
+ Our first Medtech Market Intelligence Report takes a deep dive into the CGM space
Latest Diabetes News
Beta Bionics insulin patch pump scores FDA clearance
Beta Bionics (NASDAQ: BBNX) has claimed an FDA clearance for its first patch pump insulin delivery system, amid plans to roll out an updated diabetes dosing algorithm and the launch of a new CGM partnership with Senseonics. The three-day, wearable Mint carries a 200-unit insulin reservoir as well as a combination of reusable and disposable […]
Medtronic moves to divest final stake in MiniMed
Medtronic (NYSE: MDT) is entering the final stretch of its long-running plan to split from its diabetes technology business, with the launch of an exchange offer that will allow stockholders to swap their company shares for those of the independent MiniMed (Nasdaq: MMED). With its catalog of insulin pumps, continuous glucose monitors and other diabetes […]
MiniMed wins CE mark for next-gen insulin pump, ups revenue guidance
MiniMed (Nasdaq: MMED) today reported Street-beating first-quarter revenue, upping its full-year sales guidance as it notched an early European regulatory win. The Northridge, California–based diabetes tech company, spun out of Medtronic earlier this year, announced a CE mark for its next-gen, app-controlled MiniMed Flex insulin pump — well ahead of the company’s calendar 2026 year-end target. […]
MiniMed Flex now integrated with Abbot’s Instinct sensor
MiniMed (Nasdaq: MMED) announced that the MiniMed Flex system is now commercially shipping in the U.S. with the Instinct sensor, made by Abbott. The MiniMed Flex system is MiniMed’s smallest and only app-controlled insulin pump. According to the company, Instinct is the world’s smallest sensor and offers up to 15 days of wear. Powered by SmartGuard technology, MiniMed Flex automatically adjusts insulin delivery, and the Meal Detection technology can […]
Senseonics sees activist investor take a major stake
Activist investor Sessa Capital has taken a sizeable stake in long-term, implantable CGM company Senseonics (NYSE: SENS), according to an SEC Schedule 13G filed today. The SEC filing lists Sessa directly owning 4,437,532 shares of Senseonics common stock, with warrants to buy another 8,000,000 shares of stock subject to a 9.9% blocker provision that prevents investors from […]
Abbott, Google to deliver glucose insights through artificial intelligence
Abbott (NYSE: ABT) is turning to Google’s artificial intelligence expertise to leverage more glucose insights for users of the Abbott Park, Illinois–based life science giant’s Lingo biowearable. Under a multiyear agreement announced today, ongoing glucose insights from Abbott’s Lingo biowearable will combine with Google Health’s technology to provide a more comprehensive view of people’s health. […]
Embecta Q3 results beat analyst expectations
Embecta Corp. (Nasdaq: EMBC) raised its full-year outlook for adjusted earnings per share as third-quarter results beat analyst estimates. The medtech company, a BD spinoff that specializes in insulin delivery, reported last week net income of $21.1 million, or $0.36 per share, on revenue of $271.7 million for the three months ended June 30, 2026. […]
Senseonics more than doubles Q2 revenue in post-Ascensia era
Senseonics (NYSE:SENS) stock is up more than 26% today after it reported what CEO Tim Goodnow described as the strongest quarter in the implantable, long-term CGM company’s history. BTIG analysts Marie Thibault, Alexandra Pang, and Sam Eiber noted that the European commercial transition from Ascensia Diabetes Care closed in June across all four markets, bringing […]
Tandem Diabetes Care seeing early benefits of new pay-as-you-go model
Tandem Diabetes Care (Nasdaq: TNDM) says U.S. sales of its insulin pumps were boosted by a scaled pay-as-you-go reimbursement model that’s been rolling out this year. According to the San Diego–based company’s second-quarter report, released after market close yesterday, the alternative reimbursement structure, available through patients’ pharmacy benefits rather than medical benefits, eliminates upfront pump […]
Diabetes Technology Innovations Special Report — 2026
Last year, MassDevice and Drug Delivery Business News rolled out the first edition of their Diabetes Technology Innovations Special Report. Now, we have the second edition available for free download, providing an in-depth overview of where the diabetes industry currently stands after another year of innovation and growth. The diabetes tech industry delivers some of the most advanced combinations of […]
